ClinicalTrials.gg
CompletedNCT05014412MagnetisMM-9Updated Feb 10, 2026Results posted

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

A Phase 2 interventional study of Elranatamab in Multiple Myeloma, sponsored by Pfizer. Completed at 50 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Enrollment
14th of 31
86 · median 75
Started
2021
with 5 others
Phase 2
18 of 31
12 open now
Registered
4th of 31
by date
Lead sponsor
13 of 31
Pfizer

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 14th largest by enrollment, is one of 6 that started in 2021, is one of 18 in phase 2, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and efficacy of different doses of elranatamab, as well as different intervals between doses.

Participants in the study will receive elranatamab as an injection under the skin at the study clinic. After the initial step-up doses, participants will start receiving one dose every week. The frequency of clinic visits for injections may then decrease over time. Participation will be at least two years.

Read the detailed description

The purpose of the study (Part 1 and Part 2) of the study is to evaluate the safety (in particular the rate of Grade ≥ 2 CRS) of a step-up priming dose regimen of elranatamab in participants with relapsed/refractory multiple myeloma. In addition, this study will assess the safety of different dosing regimens of elranatamab and if it can provide a clinical benefit in those participants. Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • BCMA
  • Multiple Myeloma
  • Relapse/Refractory
  • RRMM
  • Elranatamab
  • Targeted T-cell
  • MagnetisMM
  • MM9
  • Phase 2
  • B-Cell Maturation Antigen
  • monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)
  • , as defined by at least 1 of the following:

    1. Serum M-protein >0.5 g/dL by SPEP
    2. Urinary M-protein excretion >200 mg/24 hours by UPEP
    3. Serum immunoglobulin FLC≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
  • to at least one IMiD
  • Refractory to at least one PI
  • Refractory to at least one anti-CD38 antibody
  • Relapsed/refractory to last anti-myeloma regimen
  • performance status ≤1
  • Resolved acute effects of any prior therapy to baseline severity or Grade ≤1
  • Not pregnant and willing to use

Exclusion criteria

Exclusion Criteria:

  • Smoldering multiple myeloma
  • Active Plasma cell leukemia
  • POEMS syndrome
  • Amyloidosis
  • Waldenström's macroglobulinemia
  • Known active CNS involvement or clinical signs of myelomatous meningeal involvement
  • Stem cell transplant within 12 weeks prior to enrollment or active
  • Active , , SARS-CoV2, , or any active, uncontrolled bacterial, fungal, or viral infection
  • Any other active within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ or Stage 0/1 malignancy with minimal risk of recurrence per investigator.
  • Previous treatment with an anti-BCMA bispecific antibody or CAR-T cell therapy.
  • within 4 weeks of the first dose
  • Previous administration with an drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
  • Known or suspected to the study intervention, or any of its
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Part 1

    Evaluation of step-up priming dosing

    Drug: Elranatamab

  • Experimental
    Part 2A

    Dose determination

    Drug: Elranatamab

  • Experimental
    Part 2B

    Dose expansion

    Drug: Elranatamab

  • Experimental
    Part 2C

    To explore higher dose intensity

    Drug: Elranatamab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2

    CRS: supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms must include fever at the onset, and may include hypotension, hypoxia and end organ dysfunction. As per ASTCT criteria, Grade (G) 1: fever (temperature \>=38 degree Celsius), hypotension and/or hypoxia none; G 2: fever, hypotension not requiring vasopressors, hypoxia requiring low-flow nasal cannula/ facemask or blow-by; G 3: fever, hypotension requiring a vasopressor with or without vasopressin, hypoxia requiring high-flow nasal cannula/ facemask, nonrebreather mask, or Venturi mask; G 4: fever, hypotension requiring multiple vasopressors (excluding vasopressin), hypoxia requiring positive pressure. Organ toxicities associated with CRS graded according to CTCAE v5.0. G 1: Mild, G 2: Moderate, G 3: severe, and G 4: life-threatening consequences; urgent intervention indicated. G 5: death related to AE.

    Time frame: Parts 1 and 2: Cycle 1 (28 days)

Secondary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs): Part 2A

    Hematological: grade 4 neutropenia lasting \>5 days; febrile neutropenia; grade \>=3 neutropenia with infection; grade 4 thrombocytopenia; grade 3 thrombocytopenia with grade \>=2 bleeding. Non-hematological: grade \>=4 adverse events (AEs); grade 3 CRS (except CRS events: not been maximally treated or improved to grade \<=1 within 48 hours); grade 3 AEs (except: AEs attributed to a CRS event; grade 3 nausea, vomiting and diarrhea that improve to grade \<= 2 within 72 hours after maximal medical management has been initiated, grade 3 fatigue lasting \<1 week; grade 3 AEs that recover to baseline or grade 1 within 5 days); confirmed drug-induced liver injury meeting Hy's law criteria; grade 3-4 laboratory abnormalities; other clinically important or persistent AEs; Grade 3 injection site reaction. CTCAE version 5.0: Grade 1: Mild AE, Grade 2: Moderate, Grade 3: severe, and grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE.

    Time frame: Part 2A: 28 days starting from the first 116 or 152 mg dose

  2. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) [All Causalities and Treatment Related]: Parts 1 and 2

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed below: Results in death, requires inpatient hospitalization or prolongation of existing hospitalization, life-threatening, congenital anomaly/birth defect etc. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator.

    Time frame: Day 1 of dosing up to 90 days post last dose (maximum treatment duration 25 cycles, follow up to 790 days)

  3. Number of Participants With Maximum Grade 3 or 4 and Grade 5 AEs [All Causalities and Treatment Related] Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5: Parts 1 and 2

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator. AEs were graded according to NCI CTCAE version 5.0 as Grade 1 indicates Mild AE, Grade 2 indicates Moderate AE, Grade 3 indicates severe AE, and grade 4 indicates life-threatening consequences; urgent intervention indicated. Grade 5 indicates death related to AE.

    Time frame: Day 1 of dosing up to 90 days post last dose (maximum treatment duration 25 cycles, follow up to 790 days)

  4. Number of Participants With Adverse Events of Special Interest (AESI)- CRS and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) [All Causalities and Treatment Related]: Parts 1 and 2

    CRS and ICANS were assessed according to ASTCT criteria. ASTCT for ICANS: Grade 1 \[immune effector cell-associated encephalopathy (ICE, overall score range 0-10, higher score = better condition) score 7-9, awakens spontaneously\]; Grade 2 \[ICE score 3-6, awakens to voice\]; Grade 3 \[ICE score 0-2, awakens only to tactile stimulus, any clinical seizure that resolves rapidly or non-convulsive seizures on EEG that resolve with intervention, focal/local oedema on neuroimaging\]; Grade 4 \[ICE 0 (unarousable and unable to perform ICE), Unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma, Life-threatening prolonged seizure (\>5 min); or repetitive clinical or electrical seizures without return to baseline in between, deep focal motor weakness such as hemiparesis or paraparesis, Diffuse cerebral oedema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI (abducens nerve) palsy; or papilledema; or Cushing's triad\].

    Time frame: Day 1 of dosing up to 90 days post last dose (maximum treatment duration 25 cycles, follow up to 790 days)

  5. Number of Participants With Hematological Measures With Baseline CTCAE Grade >=2 Shifted to a Maximum CTCAE Grade 3-4: Parts 1 and 2

    Hematology results were graded according to the NCI CTCAE version 5.0 for relevant parameters, Grade 1 indicates Mild AE, Grade 2 indicates Moderate AE, Grade 3 indicates severe AE, and grade 4 indicates life-threatening consequences; urgent intervention indicated, Grade 5 indicates death related to AE. Hematological measures included Hemoglobin, Platelet count, WBC count, Plasma cell count. Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes, Plasma cells etc.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  6. Number of Participants With Clinical Chemistry Parameters With Baseline CTCAE Grade >=2 Shifted to a Maximum CTCAE Grade 3-4: Parts 1 and 2

    Clinical chemistry data included BUN (Blood urea nitrogen), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, Magnesium, Phosphorus or Phosphates, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total bilirubin, Alkaline phosphatase, Albumin, Chloride, Total CO2 (bicarbonate), Total protein, Lactate dehydrogenase (LDH), Uric acid, Serum beta-2 microglobulin.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  7. Number of Participants With Liver Function Tests Abnormalities: Parts 1 and 2

    Alanine aminotransferase, aspartate aminotransferase, Alkaline Phosphatase, and total bilirubin (TBILI) were used to assess possible drug induced liver toxicity.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  8. Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria as Determined by Investigator: Parts 1 and 2

    ORR: % of participants with objective response. stringent complete response (sCR):CR; ii) normal serum free light chain (FLC) ratio; absence of clonal cells in bone marrow biopsy (BMB)/ bone marrow aspirate (BMA) by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was normal serum FLC ratio of 0.26-1.65. VGPR:Serum and urine M-protein detectable by immunofixation but not on electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 h; if only measurable disease is by serum FLC levels, VGPR:\>=90% decrease in difference between involved and uninvolved serum FLC levels; in addition if present at baseline, \>90% reduction compared to baseline in size of soft tissue plasmacytomas. PR:≥50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by ≥90% or to \<200 mg/24 h.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  9. Complete Response Rate (CRR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

    CRR was defined as the percentage of participants with a BOR of confirmed sCR/CR per IMWG response criteria as determined by investigator. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  10. Time to Response (TTR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

    Time to response was defined for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that was subsequently confirmed.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  11. Duration of Response (DOR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

    DOR: time from the first documentation of objective response, until confirmed PD, or death due to any cause, whichever occurred first. PD: Increase of \>=25% from lowest confirmed response value in any 1 or more of following: serum M-component (absolute increase must be \>=0.5 g/dL); serum M-protein increase \>=1 g/dL, if lowest M component was \>=5 g/dL; urine M-protein (absolute increase must be \>=200 mg/24 h). In participants without measurable serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (absolute increase must be \>10 mg/dL). In participants without measurable serum, urine M-protein levels and involved serum FLC levels, BM plasma-cell % irrespective of baseline status (must be \>=10%). Appearance of a new lesion, \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of a previous lesion \>1 cm in short axis. \>=50% increase in circulating plasma cells (minimum of 200 cells per mcL) if only measure of disease.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  12. Duration of Complete Response Rate (DOCR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

    DOCR was defined as the time from the first documentation of sCR or CR that was subsequently confirmed, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  13. Progression Free Survival (PFS) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

    PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first. Analysis was performed using Kaplan-Meier method. Participants with no PD event or death or who started a new anticancer therapy prior to an event or with an event after a gap of 2 or more missing disease assessments were censored on the date of last adequate disease assessment. Participants who did not have an adequate post-baseline disease assessment were censored on the date of first dose of study intervention unless death occurred on or before the time of the second planned disease assessment (\<=8 weeks after the date of first dose) in which case the death was considered an event.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  14. Overall Survival (OS): Parts 1 and 2

    OS was defined as the time from the date of first dose until death due to any cause. If a participant was not known to have died, survival was censored at the date of last contact. Analysis was performed using Kaplan-Meier method.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  15. Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria: Parts 1 and 2

    MRD negativity rate was defined as the percentage of participants with negative MRD (assessed by central laboratory) per IMWG sequencing criteria at any time from the date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurred first. Sequencing MRD negative included: 1) CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65; 2) Absence of clonal plasma cells by next generation sequencing (NGS) on BMA in which presence of a clone was defined as \<2 identical sequencing reads obtained after DNA sequencing of BMA using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10\^5 nucleated cells.

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

  16. Pre- and Post-dose Concentrations of Elranatamab: Parts 1 and 2

    Time frame: Parts 1 and 2: Till study completion approximately 3 years 7 months

  17. Number of Participants With Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab) Against Elranatamab: Parts 1 and 2

    Time frame: Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

07

Results

Posted Jul 30, 2024
Limitations and caveats
ASTCT: American Society for Transplantation and Cellular Therapy. CTCAE: Common Terminology Criteria for Adverse Events. g/dl: Gram/deciliter mg: Milligram BM: Bone marrow Cm: Centimeter SPD: Sum of the products of diameters mcl: Microliter

Participant flow

In this study Part 2C was exploratory and there was no participant enrolled in Part 2C as it was not conducted. A total of 86 participants with relapsed/ refractory multiple myeloma were enrolled in this study and 85 participants were treated.

Participant flow — Overall Study
MilestonePart 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2B
Started33121129
Completed0000
Not completed33121129
Withdrew: Death11747
Withdrew: Withdrawal by subject1112
Withdrew: Ongoing214620

Outcome measures

PrimaryNumber of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2

CRS: supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms must include fever at the onset, and may include hypotension, hypoxia and end organ dysfunction. As per ASTCT criteria, Grade (G) 1: fever (temperature \>=38 degree Celsius), hypotension and/or hypoxia none; G 2: fever, hypotension not requiring vasopressors, hypoxia requiring low-flow nasal cannula/ facemask or blow-by; G 3: fever, hypotension requiring a vasopressor with or without vasopressin, hypoxia requiring high-flow nasal cannula/ facemask, nonrebreather mask, or Venturi mask; G 4: fever, hypotension requiring multiple vasopressors (excluding vasopressin), hypoxia requiring positive pressure. Organ toxicities associated with CRS graded according to CTCAE v5.0. G 1: Mild, G 2: Moderate, G 3: severe, and G 4: life-threatening consequences; urgent intervention indicated. G 5: death related to AE.

Time frame:
Parts 1 and 2: Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2
ParticipantsAll Participants
Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 212
SecondaryNumber of Participants With Dose Limiting Toxicities (DLTs): Part 2A

Hematological: grade 4 neutropenia lasting \>5 days; febrile neutropenia; grade \>=3 neutropenia with infection; grade 4 thrombocytopenia; grade 3 thrombocytopenia with grade \>=2 bleeding. Non-hematological: grade \>=4 adverse events (AEs); grade 3 CRS (except CRS events: not been maximally treated or improved to grade \<=1 within 48 hours); grade 3 AEs (except: AEs attributed to a CRS event; grade 3 nausea, vomiting and diarrhea that improve to grade \<= 2 within 72 hours after maximal medical management has been initiated, grade 3 fatigue lasting \<1 week; grade 3 AEs that recover to baseline or grade 1 within 5 days); confirmed drug-induced liver injury meeting Hy's law criteria; grade 3-4 laboratory abnormalities; other clinically important or persistent AEs; Grade 3 injection site reaction. CTCAE version 5.0: Grade 1: Mild AE, Grade 2: Moderate, Grade 3: severe, and grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE.

Time frame:
Part 2A: 28 days starting from the first 116 or 152 mg dose
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs): Part 2A
ParticipantsPart 2A: Dose Level 1Part 2A: Dose Level 2
Number of Participants With Dose Limiting Toxicities (DLTs): Part 2A11
SecondaryNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs) [All Causalities and Treatment Related]: Parts 1 and 2

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed below: Results in death, requires inpatient hospitalization or prolongation of existing hospitalization, life-threatening, congenital anomaly/birth defect etc. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator.

Time frame:
Day 1 of dosing up to 90 days post last dose (maximum treatment duration 25 cycles, follow up to 790 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) [All Causalities and Treatment Related]: Parts 1 and 2
ParticipantsPart 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2B
All cause: AE33121129
All cause: SAE2311821
Treatment related: AE32121125
Treatment related: SAE171065
SecondaryNumber of Participants With Maximum Grade 3 or 4 and Grade 5 AEs [All Causalities and Treatment Related] Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5: Parts 1 and 2

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator. AEs were graded according to NCI CTCAE version 5.0 as Grade 1 indicates Mild AE, Grade 2 indicates Moderate AE, Grade 3 indicates severe AE, and grade 4 indicates life-threatening consequences; urgent intervention indicated. Grade 5 indicates death related to AE.

Time frame:
Day 1 of dosing up to 90 days post last dose (maximum treatment duration 25 cycles, follow up to 790 days)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade 3 or 4 and Grade 5 AEs [All Causalities and Treatment Related] Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5: Parts 1 and 2
ParticipantsPart 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2B
All cause: Grades 3/4269620
All cause: Grade 55245
Treatment related: Grades 3/42310916
Treatment related: Grade 50000
SecondaryNumber of Participants With Adverse Events of Special Interest (AESI)- CRS and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) [All Causalities and Treatment Related]: Parts 1 and 2

CRS and ICANS were assessed according to ASTCT criteria. ASTCT for ICANS: Grade 1 \[immune effector cell-associated encephalopathy (ICE, overall score range 0-10, higher score = better condition) score 7-9, awakens spontaneously\]; Grade 2 \[ICE score 3-6, awakens to voice\]; Grade 3 \[ICE score 0-2, awakens only to tactile stimulus, any clinical seizure that resolves rapidly or non-convulsive seizures on EEG that resolve with intervention, focal/local oedema on neuroimaging\]; Grade 4 \[ICE 0 (unarousable and unable to perform ICE), Unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma, Life-threatening prolonged seizure (\>5 min); or repetitive clinical or electrical seizures without return to baseline in between, deep focal motor weakness such as hemiparesis or paraparesis, Diffuse cerebral oedema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI (abducens nerve) palsy; or papilledema; or Cushing's triad\].

Time frame:
Day 1 of dosing up to 90 days post last dose (maximum treatment duration 25 cycles, follow up to 790 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESI)- CRS and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) [All Causalities and Treatment Related]: Parts 1 and 2
ParticipantsPart 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2B
All cause: CRS20101014
All cause: ICANS1120
Treatment related: CRS20101013
Treatment related: ICANS1120
SecondaryNumber of Participants With Hematological Measures With Baseline CTCAE Grade >=2 Shifted to a Maximum CTCAE Grade 3-4: Parts 1 and 2

Hematology results were graded according to the NCI CTCAE version 5.0 for relevant parameters, Grade 1 indicates Mild AE, Grade 2 indicates Moderate AE, Grade 3 indicates severe AE, and grade 4 indicates life-threatening consequences; urgent intervention indicated, Grade 5 indicates death related to AE. Hematological measures included Hemoglobin, Platelet count, WBC count, Plasma cell count. Absolute: Neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes, Plasma cells etc.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Chemistry Parameters With Baseline CTCAE Grade >=2 Shifted to a Maximum CTCAE Grade 3-4: Parts 1 and 2

Clinical chemistry data included BUN (Blood urea nitrogen), Creatinine, Glucose (non-fasting), Total Calcium, Sodium, Potassium, Chloride, Magnesium, Phosphorus or Phosphates, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total bilirubin, Alkaline phosphatase, Albumin, Chloride, Total CO2 (bicarbonate), Total protein, Lactate dehydrogenase (LDH), Uric acid, Serum beta-2 microglobulin.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Liver Function Tests Abnormalities: Parts 1 and 2

Alanine aminotransferase, aspartate aminotransferase, Alkaline Phosphatase, and total bilirubin (TBILI) were used to assess possible drug induced liver toxicity.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria as Determined by Investigator: Parts 1 and 2

ORR: % of participants with objective response. stringent complete response (sCR):CR; ii) normal serum free light chain (FLC) ratio; absence of clonal cells in bone marrow biopsy (BMB)/ bone marrow aspirate (BMA) by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was normal serum FLC ratio of 0.26-1.65. VGPR:Serum and urine M-protein detectable by immunofixation but not on electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 h; if only measurable disease is by serum FLC levels, VGPR:\>=90% decrease in difference between involved and uninvolved serum FLC levels; in addition if present at baseline, \>90% reduction compared to baseline in size of soft tissue plasmacytomas. PR:≥50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by ≥90% or to \<200 mg/24 h.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryComplete Response Rate (CRR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

CRR was defined as the percentage of participants with a BOR of confirmed sCR/CR per IMWG response criteria as determined by investigator. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryTime to Response (TTR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

Time to response was defined for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that was subsequently confirmed.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

DOR: time from the first documentation of objective response, until confirmed PD, or death due to any cause, whichever occurred first. PD: Increase of \>=25% from lowest confirmed response value in any 1 or more of following: serum M-component (absolute increase must be \>=0.5 g/dL); serum M-protein increase \>=1 g/dL, if lowest M component was \>=5 g/dL; urine M-protein (absolute increase must be \>=200 mg/24 h). In participants without measurable serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (absolute increase must be \>10 mg/dL). In participants without measurable serum, urine M-protein levels and involved serum FLC levels, BM plasma-cell % irrespective of baseline status (must be \>=10%). Appearance of a new lesion, \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of a previous lesion \>1 cm in short axis. \>=50% increase in circulating plasma cells (minimum of 200 cells per mcL) if only measure of disease.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryDuration of Complete Response Rate (DOCR) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

DOCR was defined as the time from the first documentation of sCR or CR that was subsequently confirmed, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryProgression Free Survival (PFS) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2

PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first. Analysis was performed using Kaplan-Meier method. Participants with no PD event or death or who started a new anticancer therapy prior to an event or with an event after a gap of 2 or more missing disease assessments were censored on the date of last adequate disease assessment. Participants who did not have an adequate post-baseline disease assessment were censored on the date of first dose of study intervention unless death occurred on or before the time of the second planned disease assessment (\<=8 weeks after the date of first dose) in which case the death was considered an event.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryOverall Survival (OS): Parts 1 and 2

OS was defined as the time from the date of first dose until death due to any cause. If a participant was not known to have died, survival was censored at the date of last contact. Analysis was performed using Kaplan-Meier method.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryMinimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria: Parts 1 and 2

MRD negativity rate was defined as the percentage of participants with negative MRD (assessed by central laboratory) per IMWG sequencing criteria at any time from the date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurred first. Sequencing MRD negative included: 1) CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65; 2) Absence of clonal plasma cells by next generation sequencing (NGS) on BMA in which presence of a clone was defined as \<2 identical sequencing reads obtained after DNA sequencing of BMA using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10\^5 nucleated cells.

Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

SecondaryPre- and Post-dose Concentrations of Elranatamab: Parts 1 and 2
Time frame:
Parts 1 and 2: Till study completion approximately 3 years 7 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab) Against Elranatamab: Parts 1 and 2
Time frame:
Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)

Results for this outcome have not been posted.

Adverse events

Collected over Day 1 of dosing up to 90 days post last dose (maximum treatment duration 25 cycles, follow up to 790 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 113/33 (39.4%)23/33 (69.7%)33/33 (100%)
Part 2A: Dose Level 18/12 (66.7%)11/12 (91.7%)12/12 (100%)
Part 2A: Dose Level 24/11 (36.4%)8/11 (72.7%)10/11 (90.9%)
Part 2B8/29 (27.6%)21/29 (72.4%)28/29 (96.6%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPart 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2B
Cytokine release syndromeImmune system disorders6/336/123/113/29
PneumoniaInfections and infestations3/330/123/111/29
COVID-19 pneumoniaInfections and infestations1/333/121/111/29
Disease progressionGeneral disorders3/331/122/113/29
Lower respiratory tract infectionInfections and infestations0/332/120/110/29
SARS-CoV-2 test positiveInvestigations0/332/120/110/29
Adenovirus infectionInfections and infestations0/330/121/110/29
CellulitisInfections and infestations1/330/121/111/29
Enterovirus infectionInfections and infestations0/330/121/110/29
Pneumonia proteusInfections and infestations0/330/121/110/29
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPart 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2B
Cytokine release syndromeImmune system disorders15/337/128/1113/29
NeutropeniaBlood and lymphatic system disorders19/337/126/1114/29
FatigueGeneral disorders13/337/126/1113/29
Injection site reactionGeneral disorders10/337/123/118/29
Decreased appetiteMetabolism and nutrition disorders13/337/123/117/29
AnaemiaBlood and lymphatic system disorders15/336/125/1115/29
DiarrhoeaGastrointestinal disorders17/336/122/119/29
ThrombocytopeniaBlood and lymphatic system disorders6/336/124/1113/29
PyrexiaGeneral disorders14/334/120/114/29
Back painMusculoskeletal and connective tissue disorders6/335/121/115/29

Baseline characteristics

All enrolled participants who received at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Part 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2BTotal
Mean60.4 ± 10.1464.0 ± 8.7566.8 ± 11.1264.1 ± 8.0863.0 ± 9.53
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2BTotal
Female19451543
Male14861442
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2BTotal
Hispanic or Latino20125
Not Hispanic or Latino301292273
Unknown or Not Reported10157
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1Part 2A: Dose Level 1Part 2A: Dose Level 2Part 2BTotal
American Indian or Alaska Native00000
Asian1953835
Native Hawaiian or Other Pacific Islander00000
Black or African American20114
White11671741
More than one race00000
Unknown or Not Reported11035
08

Study locations

50 sites
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Poudre Valley Hospital
    Fort Collins, Colorado 80524, United States
  • Cancer Care & Hematology - Fort Collins
    Fort Collins, Colorado 80528, United States
  • Poudre Valley Health System (PVHS)
    Fort Collins, Colorado 80528, United States
  • UCHealth Cancer Care & Hematology - Greeley
    Greeley, Colorado 80634, United States
  • UCHealth Cancer Care & Hematology - Loveland
    Loveland, Colorado 80538, United States
  • UF Health Shands Cancer Hospital
    Gainesville, Florida 32608, United States
  • UF Health Shands Hospital Pharmacy Investigational Drug Service - Main
    Gainesville, Florida 32610, United States
  • UF Health Shands Hospital
    Gainesville, Florida 32610, United States
  • East Jefferson General Hospital Bone Marrow Transplant Clinic
    Metairie, Louisiana 70006, United States
  • East Jefferson General Hospital
    Metairie, Louisiana 70006, United States
  • Tulane University
    New Orleans, Louisiana 70112, United States
  • The Regents of the University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • MSK Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • MSK Monmouth
    Middletown, New Jersey 07748, United States
  • MSK Bergen
    Montvale, New Jersey 07645, United States
  • MSK Commack
    Commack, New York 11725, United States
  • MSK Westchester
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
    Long Island City, New York 11101, United States
  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
    New York, New York 10021, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • MSK Nassau
    Uniondale, New York 11553, United States
  • Cleveland Clinic Taussig Cancer Institute
    Cleveland, Ohio 44195, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • St. David's South Austin Medical Center
    Austin, Texas 78704, United States
  • Texas Oncology-South Austin
    Austin, Texas 78745, United States
  • Blood Cancer and Stem Cell Transplant Clinic
    San Antonio, Texas 78229, United States
  • Methodist Healthcare System of San Antonio dba Methodist Hospital
    San Antonio, Texas 78229, United States
  • Methodist Hospital Investigational Pharmacy
    San Antonio, Texas 78229, United States
  • Methodist Plaza Clinical Trials Office
    San Antonio, Texas 78229, United States
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
  • Kobe City Medical Center General Hospital
    Kobe, Hyōgo 650-0047, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Japanese Red Cross Medical Center
    Shibuya-ku, Tokyo 150-8935, Japan
  • University Hospital,Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2TH, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, NW1 2PG, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust
    London, SE1 9RT, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SW3 6JJ, United Kingdom
  • University College London Hospitals NHS Foundation Trust NIHR
    London, W1T 7HA, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Surrey, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Hibma JE, Irby D, Liu A, Elmeliegy M, King LE, Gifondorwa D, Jiang S, Poels KE, Soltantabar P, Lon HK, Shtylla B, Wang D, Williams JH, Nicholas T. Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2026 Jun 13. doi: 10.1007/s40262-026-01663-z. Online ahead of print. PubMed 42287565 ↗
  • Lon HK, Hibma J, Jiang S, Sullivan S, Vandendries E, Skoura A, Wang D, Elmeliegy M. Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma. Target Oncol. 2025 Sep;20(5):803-819. doi: 10.1007/s11523-025-01168-y. Epub 2025 Aug 18. PubMed 40826257 ↗
  • Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, Hibma J, Lon HK, Piscitelli J, Soltantabar P, Skoura A, Jiang S, Wang D. Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Target Oncol. 2025 Mar;20(2):349-359. doi: 10.1007/s11523-025-01134-8. Epub 2025 Feb 25. PubMed 40000533 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jun 2023, 20 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 20 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 20, 2021
StartActual
Oct 7, 2021
Primary completionActual
Jun 15, 2023
CompletionActual
Dec 12, 2025
Results first posted
Jul 30, 2024
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05014412
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Oct 7, 2021
Primary completion
Jun 15, 2023
Completion
Dec 12, 2025
Results posted
Jul 30, 2024
Last update
Feb 10, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elranatamab

Start the discussion